{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:40:13Z","timestamp":1790073613281,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ahj.2026.107451","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:12:25Z","timestamp":1776957145000},"page":"107451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study"],"prefix":"10.1016","volume":"299","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1107-2513","authenticated-orcid":false,"given":"Hanae F.","family":"Namba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elize A.M.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen K.M.","family":"Boerhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimane","family":"Mechroubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Nijkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukelien C.","family":"Dimitriu-Leen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Meuwissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton A.C.M.","family":"Heestermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina C.","family":"den Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel A.M.","family":"Beijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola S.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Escaned","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester M.","family":"den Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Appelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etto C.","family":"Eringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Delewi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Piek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-0619","authenticated-orcid":false,"given":"Tim P.","family":"van de Hoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107451_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf580","article-title":"Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial","author":"Boerhout","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107451_bib0002","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107451_bib0003","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1093\/eurheartj\/ehaa503","volume":"41","author":"Kunadian","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107451_bib0004","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1253\/circj.CJ-22-0779","article-title":"JCS\/CVIT\/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction","volume":"87","author":"Hokimoto","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2026.107451_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012017","article-title":"Presence of coronary endothelial dysfunction, coronary vasospasm, and adenosine-mediated vasodilatory disorders in patients with ischemia and nonobstructive coronary arteries","volume":"15","author":"Feenstra","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2026.107451_bib0006","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijcard.2021.02.079","article-title":"Vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease is dominated by vasospasm","volume":"333","author":"Konst","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2026.107451_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcin.2021.10.003","article-title":"Acetylcholine rechallenge: a first step toward tailored treatment in patients with coronary artery spasm","volume":"15","author":"Seitz","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2026.107451_bib0008","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pharmthera.2007.06.012","article-title":"Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?","author":"Chirkov","year":"2007","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.ahj.2026.107451_bib0009","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrd2222","article-title":"Peroxynitrite: biochemistry, pathophysiology and development of therapeutics","author":"Szab\u00f3","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ahj.2026.107451_bib0010","doi-asserted-by":"crossref","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","author":"Pacher","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ahj.2026.107451_bib0011","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jaccas.2020.11.043","article-title":"Repurposing riociguat for treatment of refractory angina resulting from coronary spasm","volume":"3","author":"Mart\u00ednez Pereyra","year":"2021","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.ahj.2026.107451_bib0012","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13543776.2021.1866538","article-title":"Soluble guanylate cyclase stimulators and their potential use: a patent review","author":"Sandner","year":"2021","journal-title":"Exp Opin Therapeut Patents"},{"key":"10.1016\/j.ahj.2026.107451_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1156456","article-title":"Drug repurposing\u2014a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)","author":"McChord","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ahj.2026.107451_bib0014","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107451_bib0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2026.107451_bib0016","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","article-title":"No- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle","volume":"136","author":"Stasch","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ahj.2026.107451_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000536","article-title":"The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction","author":"Greene","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107451_bib0018","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1172\/JCI28371","article-title":"Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels","volume":"116","author":"Stasch","year":"2006","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ahj.2026.107451_bib0019","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107451_bib0020","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"Rationale and design of the soluble guanylate cyclase stimulator in heart failure studies (SOCRATES)","volume":"16","author":"Pieske","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2026.107451_bib0021","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients withworsening chronic heart failure and reduced ejection fraction the socrates-reduced randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107451_bib0022","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cpt.2574","article-title":"Vericiguat in combination with short-acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase ib, VENICE study","volume":"111","author":"Boettcher","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2026.107451_bib0023","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/cts.13238","article-title":"Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: the randomized, phase ib, VISOR study","volume":"15","author":"Boettcher","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ahj.2026.107451_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2023.02.043","article-title":"Design and rationale of the NetherLands registry of invasive coronary vasomotor function testing (NL-CFT)","volume":"379","author":"Crooijmans","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2026.107451_bib0025","first-page":"2565","article-title":"International standardization of diagnostic criteria for vasospastic angina","volume":"38","author":"Beltrame","year":"2017","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ahj.2026.107451_bib0026","doi-asserted-by":"crossref","first-page":"H1086","DOI":"10.1152\/ajpheart.00335.2024","article-title":"Relationship between peripheral and intracoronary blood flow in patients with angina and non-obstructive coronary arteries","volume":"327","author":"Woudstra","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ahj.2026.107451_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1117\/1.JBO.24.8.080901","article-title":"Clinical applications of laser speckle contrast imaging: a review","volume":"24","author":"Heeman","year":"2019","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.ahj.2026.107451_bib0028","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCIMAGING.111.970418","article-title":"Assessment of skin microvascular function and dysfunction with laser speckle contrast imaging","volume":"5","author":"Mah\u00e9","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2026.107451_bib0029","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1093\/eurheartj\/ehy529","article-title":"Systemic microvascular dysfunction in microvascular and vasospastic angina","volume":"39","author":"Ford","year":"2018","journal-title":"Eur Heart J"},{"issue":"4 Pt 2","key":"10.1016\/j.ahj.2026.107451_bib0030","first-page":"H1435","article-title":"Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide","volume":"270","author":"Meredith","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ahj.2026.107451_bib0031","doi-asserted-by":"crossref","DOI":"10.3791\/2167","article-title":"Assessing endothelial vasodilator function with the endo-PAT 2000","author":"Axtell","year":"2010","journal-title":"J Visual Exp"},{"key":"10.1016\/j.ahj.2026.107451_bib0032","doi-asserted-by":"crossref","first-page":"H32","DOI":"10.1093\/eurheartjsupp\/suac058","article-title":"Remote digital smart device follow-up in prospective clinical trials: early insights from ORBITA-2, ORBITA-COSMIC, and ORBITA-STAR","volume":"24","author":"Ganesananthan","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107451_bib0033","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2026.107451_bib0034","doi-asserted-by":"crossref","first-page":"h5527","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2026.107451_bib0035","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20165541","article-title":"A novel effective method for the assessment of microvascular function in male patients with coronary artery disease: a pilot study using laser speckle contrast imaging","volume":"49","author":"Borges","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.ahj.2026.107451_bib0036","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jdiacomp.2016.12.007","article-title":"Assessment of microvascular endothelial function in type 1 diabetes using laser speckle contrast imaging","volume":"31","author":"De Matheus","year":"2017","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.ahj.2026.107451_bib0037","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(24)00256-3","article-title":"Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial","volume":"403","author":"Foley","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107451_bib0038","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.jacc.2018.09.006","article-title":"Stratified medical therapy using invasive coronary function testing in Angina: the CorMicA trial","volume":"72","author":"Ford","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107451_bib0039","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/0735-1097(93)90310-W","article-title":"Randomized placebo-controlled trial of Amlodipine in vasospastic angina","volume":"21","author":"Chahine","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107451_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239039","article-title":"Comparison of nebivolol versus diltiazem in improving coronary artery spasm and quality of life in patients with hypertension and vasospastic angina: a prospective, randomized, double-blind pilot study","volume":"15","author":"Kook","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2026.107451_bib0041","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jcmg.2022.03.012","article-title":"Efficacy of diltiazem to improve coronary vasomotor dysfunction in ANOCA: the EDIT-CMD randomized clinical trial","volume":"15","author":"Jansen","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2026.107451_bib0042","article-title":"Efficacy and safety of the endothelin-1 receptor antagonist macitentan in epicardial and microvascular vasospasm; a proof-of-concept study","volume":"47","author":"Feenstra","year":"2023","journal-title":"IJC Heart Vasc"},{"key":"10.1016\/j.ahj.2026.107451_bib0043","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.124.069901","article-title":"Zibotentan in microvascular angina: a randomized, placebo-controlled, crossover trial","author":"Morrow","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107451_bib0044","series-title":"American College of Cardiology Annual Scientific Session (ACC 25)","article-title":"Women\u2019s ischemia trial to reduce events in non-obstructive CAD-WARRIOR","author":"Pepine","year":"2025"},{"key":"10.1016\/j.ahj.2026.107451_bib0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ahj.2025.04.022","article-title":"Design and rationale of the efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled trial (EDIT-CAS)","volume":"288","author":"Crooijmans","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107451_bib0046","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/01.RES.0000184694.03262.6d","article-title":"Explaining the phenomenon of nitrate tolerance","author":"M\u00fcnzel","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2026.107451_bib0047","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326001134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326001134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:52:20Z","timestamp":1780775540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326001134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"alternative-id":["S0002870326001134"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107451","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107451"}}